Polyphor achieves first milestone in macrocycle drug discovery collaboration with Boehringer Ingelheim
Allschwil, Switzerland, July 31, 2013 - Polyphor, a research-driven pharmaceutical company and leader in the discovery and development of macrocyclic drugs, today announced that Boehringer Ingelheim has decided to enter into the next stage of its drug discovery collaboration with Polyphor. Financial details were not disclosed.
This collaborative project was originally initiated in June 2012 with the objective to discover and develop novel macrocyclic compounds for targets nominated by Boehringer Ingelheim. Following the successful hit identification phase, the parties have now agreed to move forward to generate candidates suitable for pre-clinical development.
Dr. Daniel Obrecht, co-founder and CSO of Polyphor, commented:
'We are extremely pleased to move this collaboration with Boehringer Ingelheim to the next research stage. This achievement clearly demonstrates that our proprietary MacroFinder® platform can successfully address difficult intracellular targets where small molecule approaches have failed so far. We look forward to extending and further strengthening the collaboration with our research partners at Boehringer Ingelheim."
About the Polyphor & Boehringer Ingelheim alliance
In June 2012 Polyphor entered into a multi-year, multi-target drug discovery alliance with Boehringer Ingelheim in which Polyphor is applying its proprietary MacroFinder® drug discovery technology to identify and optimize novel macrocyclic drug candidates addressing challenging therapeutic targets selected by Boehringer Ingelheim. Boehringer Ingelheim will then be solely responsible for subsequent development and commercialization of the identified drug candidates. In return, Polyphor receives an up-front payment, research funding, milestone payments and royalties on the commercial sales of any approved products.
About MacroFinder® Technology
Polyphor's MacroFinder® drug discovery platform provides fully synthetic, macrocyclic molecules able to effectively modulate complex biological targets, including intra- and extracellular protein-protein interactions. MacroFinder® compounds consist of several subunits, which can be efficiently assembled in a modular fashion by high yielding organic chemistry transformations. The variation of these subunits can be used to subtly modulate activity, selectivity and ADMET properties such as cell permeability and oral bioavailability.
About Polyphor Ltd
Polyphor Ltd is a privately held, Swiss, research-driven pharmaceutical company founded in 1996. It is specialized in the discovery and development of macrocyclic drugs offering new, innovative therapeutic options. Polyphor has developed a proprietary macrocycle drug discovery technology platform, built-up an attractive portfolio of drug candidates and evolved into a clinical stage company.
Its product portfolio includes:
- POL6326, a CXCR4 antagonist, with ongoing and upcoming Phase II clinical trials for stem cell transplantation, tissue repair and combination treatments in oncology;
- POL7080, a highly specific antibiotic with a novel mode of action to treat life-threatening Pseudomonas infections (Phase II);
- POL6014, an inhibitor of neutrophil elastase which may lead to a breakthrough therapy for serious lung diseases such as Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and other lung diseases (ready for IND enabling studies).
In addition, Polyphor has established R&D collaborations with Novartis and Boehringer Ingelheim, which are based on its macrocycle technology platform.
For additional information, please visit www.polyphor.com
Michael Altorfer, Ph.D.
Head Corporate Communications
t: +41 61 567 16 00
e: [email protected]